Company Overview

Polarean Imaging plc is a medical imaging technology company focused on advanced pulmonary imaging using hyperpolarized xenon-129 (Xe-129) magnetic resonance imaging (MRI). The company operates within the medical imaging, pulmonary diagnostics, and healthcare technology sectors, with a primary emphasis on improving visualization and assessment of lung function. Its core commercial platform is the Xenoview imaging agent and associated MRI imaging workflow, which enables clinicians to evaluate regional lung ventilation and gas exchange in ways that conventional imaging modalities may not provide. The company primarily serves hospitals, academic medical centers, pulmonary specialists, and research institutions involved in respiratory disease diagnosis and monitoring.

The company traces its origins to technology developed at academic institutions focused on hyperpolarized gas MRI research and was incorporated in the United Kingdom while maintaining significant operational activities in the United States. Polarean evolved from a research-oriented imaging technology developer into a commercial-stage healthcare company following U.S. regulatory clearance for its Xenoview platform. Its strategic positioning is based on proprietary hyperpolarization technology, specialized imaging expertise, and early-mover status in functional pulmonary MRI, particularly in diseases such as chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease, and cystic fibrosis.

Business Operations

Polarean generates revenue through the commercialization of its hyperpolarized gas imaging platform, including the sale and distribution of Xenoview, associated hardware, service arrangements, and support for clinical and research imaging programs. The company’s operations are centered around its pulmonary functional imaging business, with activities spanning clinical commercialization, regulatory support, imaging agent production, and collaborative research initiatives. Its primary operating focus has been the United States market following U.S. Food and Drug Administration approval of Xenoview for use with MRI evaluation of lung ventilation in certain patient populations.

The company controls proprietary polarization technology used to prepare xenon gas for MRI imaging applications and maintains intellectual property related to hyperpolarized gas imaging systems. Polarean has collaborated with imaging institutions, academic hospitals, and MRI ecosystem participants to support adoption of Xe-129 MRI workflows. The company has also worked alongside major MRI scanner manufacturers and pulmonary research centers to facilitate integration of its imaging platform into clinical practice and multicenter studies. Public disclosures identify operational subsidiaries including Polarean, Inc., which serves as a key U.S.-based operating entity.

Strategic Position & Investments

Polarean’s strategic direction centers on expanding adoption of functional lung MRI as a clinical tool and broadening reimbursement, physician awareness, and research utilization of Xenoview imaging. Growth initiatives have included commercialization efforts targeting leading pulmonary and academic centers, expansion of imaging site installations, and continued clinical evidence generation supporting pulmonary disease applications. The company has also invested in physician education, regulatory engagement, and multicenter clinical collaborations designed to support broader market penetration.

The company’s investment priorities have focused on imaging technology advancement, commercialization infrastructure, and clinical validation initiatives. Polarean has pursued intellectual property development related to hyperpolarization systems and gas imaging workflows while positioning itself within emerging precision medicine approaches for respiratory disease. Public filings and investor disclosures indicate continuing interest in expanding applications of hyperpolarized MRI into additional pulmonary indications and potentially broader functional imaging use cases. Data regarding large-scale acquisitions or extensive portfolio holdings remains limited based on available public sources.

Geographic Footprint

Polarean Imaging plc is headquartered in the United Kingdom, while maintaining substantial operational and commercial activities in the United States, particularly through its U.S. subsidiary structure and commercialization efforts. The company’s imaging technology has been utilized across leading academic and clinical research institutions in North America and selected international research centers involved in pulmonary imaging studies.

The company’s market presence has primarily focused on the U.S. healthcare market, where regulatory authorization has enabled commercial deployment of Xenoview. Polarean also maintains relationships with international clinical and academic collaborators in Europe and other research-oriented medical imaging markets. Although global commercialization remains comparatively limited relative to larger imaging companies, the company has sought to establish influence within specialized pulmonary imaging and respiratory research networks internationally.

Leadership & Governance

Polarean’s leadership structure combines medical imaging, healthcare commercialization, regulatory, and financial expertise. The company’s governance approach has emphasized clinical validation, disciplined commercialization, and strategic expansion of functional pulmonary imaging technologies. Public company disclosures, including annual reports and regulatory filings, indicate that leadership has prioritized long-term clinical adoption and evidence-based commercialization following regulatory approval milestones.

Key executives and directors publicly associated with the company include:

• Christopher von Jako – Chief Executive Officer
• Kenneth J. West – Chief Financial Officer
• Charles H. Pickering, PhD – Chief Scientific Officer
• Richard Morgan – Non-Executive Chairman

Leadership communications in public filings and investor materials consistently emphasize expanding clinical access to functional lung imaging, strengthening reimbursement pathways, and supporting research partnerships aimed at advancing pulmonary disease assessment technologies.